Fig. 8

NRF2 antagonists counteract the ameliorating effects of Sirt6 on inflammation and oxidative stress. A Immunofluorescence images of Nfκb-p65, CD68, and TNF-α in BV2 cells with combined Sirt6 overexpression and NRF2 antagonist treatment. Scale bars: 10 μm. B Quantitative analysis of immunofluorescent intensity of Nfκb-p65, CD68, and TNF-α in BV2 cells with combined Sirt6 overexpression and NRF2 antagonist treatment. n = 4/group. C Expression of inflammatory cytokines TNF-α and IL-6. n = 6–7/group. D mRNA expression of Tnf-α, Il-6, Il-1β, and Cox-2. n = 9–12/group. E Immunofluorescence images of ROS. Scale bars: 100 μm. F mRNA expression levels of Gclm and Sod2. n = 9/group. B-D, F Two-way ANOVA analysis followed by the Tukey post hoc test were performed. ns: not significant. Data are presented as mean ± SEM, * p < 0.05, ** p < 0.01, *** p < 0.001